LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections

BACKGROUND: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat associated with significant mortality and medical cost. Microbiota therapy is gaining acceptance as a strategy to reduce rCDI recurrence. We present the final 24-month analysis of clinical safety, effic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Orenstein, Robert, Mische, Sarah, Blount, Ken, Bancke, Lindy, Su, Xin, Walsh, Dana, Harvey, Adam, Gonzalez, Carlos, Gerding, Dale N
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810069/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz415.2488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados